extract
spong
genu
mycal
new
zealand
otago
harbour
yield
small
quantiti
brown
oil
mg
g
spong
whose
bioactiv
compon
exhibit
unusu
ring
system
known
mycalamid
structur
mycalamid
b
remark
similar
insect
toxin
pederin
exhibit
potent
compar
cytotox
antitumor
activ
despit
product
highli
distinct
speci
common
mycalamid
pederin
subsequ
discov
onnamid
antivir
compound
japanes
spong
indic
like
relat
mode
biosynthesi
pederin
found
beetl
eg
paederu
fuscip
structur
consid
polyketid
bear
vesic
potent
antitumor
properti
although
pederin
weak
antibacteri
properti
sever
toxic
eukaryot
cell
properti
like
stem
abil
block
protein
synthesi
cell
divis
signific
evid
indic
pederin
synthes
bacteri
symbiont
host
beetl
perhap
close
rel
p
aeruginosa
find
rais
possibl
cultur
bacteria
gener
larg
quantiti
pederin
therapeut
use
chemic
modif
enhanc
pharmacodynamicspharmacokinet
current
howev
isol
practic
quantiti
pederin
biolog
sourc
remain
challeng
approxim
lb
million
insect
need
extract
enough
pederin
structur
analysi
scheme
comprehens
character
pharmacodynam
toxicolog
therapeut
potenti
congen
limit
pauciti
therefor
altern
practic
synthet
approach
prove
highli
use
remark
potent
set
compound
develop
new
effici
synthet
strategi
facilit
product
new
lead
modif
ideal
deriv
natur
compound
suitabl
pharmacodynam
pharmacokinet
properti
importantli
tissu
target
may
becom
realist
goal
account
major
synthet
strategi
produc
compound
mycalamid
pederin
psymberin
famili
present
separ
section
present
method
reflect
clear
masteri
modern
synthesi
techniqu
reagent
investig
sever
synthet
strategi
produc
mycalamid
publish
propos
method
date
complex
strategi
low
yield
ad
complex
strategi
requir
stereospecif
sever
step
thu
develop
effici
synthet
strategi
critic
realiz
full
potenti
class
compound
synthet
approach
produc
right
half
mycalamid
demonstr
use
kishi
method
techniqu
util
start
materi
earli
multistep
sequenc
develop
signific
portion
mycalamid
structur
publish
basic
synthet
strategi
involv
alter
previous
publish
methodolog
conjug
method
produc
total
mycalamid
requir
activ
peder
left
portion
molecul
ptoluenesulfonyl
chloridedmapdichloromethan
room
temperatur
follow
treatment
amin
produc
hydrogen
azid
roush
method
excel
chiral
precursor
methyl
use
effect
control
stereoselect
coupl
strategi
gener
amid
bridg
altern
approach
synthes
methyl
peder
acid
involv
peder
intermedi
kishi
synthesi
mycalamid
b
onnamid
scheme
depict
significantli
diastereoselect
synthesi
incorpor
exo
methylen
moieti
involv
use
import
takainozaki
protocol
zn
thf
strategi
produc
peder
acid
deriv
employ
synthesi
one
key
step
method
mismatch
aldol
reaction
imid
aldehyd
step
yield
ca
mixtur
two
isomer
aldol
incorrect
stereochemistri
enrich
isomer
mixtur
mycalamid
requir
epimer
betaketo
imid
step
diverg
effect
approach
involv
swern
style
oxid
isomer
mixtur
aldol
approach
proce
reaction
condit
minim
epimer
select
yield
strategi
produc
methyl
mycalamid
intermedi
report
trotter
et
al
nakata
group
effect
strategi
employ
wellknown
nakata
precursor
util
similar
method
result
gener
basic
framework
system
one
limit
approach
conjug
strategi
employ
origin
techniqu
yield
isomer
mixtur
target
product
product
challeng
purifi
stereoselect
focu
toyota
sihara
method
mycalamid
synthesi
procedur
dmannitol
use
chiral
precursor
eventu
product
right
half
mycalamid
structur
strategi
lewisacidcatalyz
intermolecular
aldol
reaction
oxypallad
critic
step
approach
yield
effect
protect
right
half
mycalamid
structur
prime
function
conjug
remain
half
structur
total
synthesi
mycalamid
kagawa
toyota
produc
ester
dmannitol
describ
ester
use
synthes
intermedi
left
right
portion
join
transmethyl
intermedi
subsequ
conjug
result
vinyl
anion
ester
group
regioselect
via
nucleophil
addit
effect
produc
final
precursor
yield
modif
function
group
precursor
produc
mycalamid
trost
probst
demonstr
approach
synthesi
method
synthes
lefthalf
mycalamid
righthalf
mycalamid
r
pantolacton
multistep
sequenc
use
form
termin
azid
right
half
suitabl
conjug
left
half
yield
total
mycalamid
sohn
rawal
approach
mycalamid
synthesi
employ
converg
coupl
peder
acid
structur
scheme
mycalamin
structur
b
approach
left
portion
acid
produc
step
overal
yield
major
step
method
palladium
ii
catalyz
tandem
wackerheck
cycliz
reaction
form
tetrahydropyran
ring
scheme
prior
coupl
right
half
mycalamid
right
half
mycalamin
structur
b
synthes
diethyl
dtartar
step
yield
join
two
halv
stereoselect
accomplish
via
dccdmap
catalysi
yield
mycalamid
reaction
pyaopdipea
produc
c
epimycalamid
yield
earlier
year
recent
time
mani
literatur
report
describ
total
synthesi
pederin
precursor
relat
structur
total
synthesi
pederamid
hydrolysi
product
pederin
first
report
tsuzuki
cowork
subsequ
nakata
et
al
report
first
synthet
method
product
total
pederin
method
stereoselect
produc
benzoylselenopeder
acid
via
novel
reduc
agent
zn
two
major
step
procedur
construct
amin
linker
use
metallateddihydropyran
product
nacyl
amin
via
rhodiumcatalyz
reduct
hydrobor
acyl
amin
kocienski
strategi
right
portion
templat
origin
describ
one
use
synthet
method
effici
product
import
precursor
whole
famili
mycalamid
rel
new
approach
publish
floreancig
et
al
employ
paterson
pinenederiv
boron
enolatealdol
strategi
effect
strategi
proce
highli
stereoselectivealdol
reaction
reaction
pivot
step
ensur
appropri
orient
bond
anoth
approach
total
synthesi
pederin
report
jewett
rawal
group
achiev
direct
coupl
left
right
halv
use
peder
acid
chlorid
lithium
anion
carbam
toluenepyridin
solut
approach
highli
effect
deprotect
step
complet
approach
requir
use
tbutyl
ammonium
fluorid
tbaf
tetrahydrofuran
solut
follow
hydrolyt
quench
lithium
hydroxid
methanol
strategi
result
format
total
pederin
mark
yield
scheme
variou
divers
method
product
peder
acid
ester
serv
specif
templat
coupl
approach
also
publish
psymberin
first
isol
crew
et
al
marin
spong
psammocinia
use
bioassayguid
fraction
method
irciniastatin
isol
pettit
et
al
year
marin
spong
ircinia
ramos
found
ident
psymberin
amid
side
chain
psymberin
focu
william
et
al
report
group
employ
xray
crystallographi
synthet
model
compound
comparison
natur
psymberin
determin
anti
configur
side
chain
natur
form
crew
cowork
also
report
assign
absolut
stereochemistri
psymberin
multipl
noe
enhanc
psymberin
assess
vitro
activ
impress
human
cancer
cell
line
gener
psymberin
stereoisom
report
de
braband
et
al
follow
year
group
report
synthesi
novel
compound
share
characterist
psymberin
pederin
refer
new
compound
psympederin
hybrid
depict
scheme
start
diol
conveni
acetyl
acid
catalysi
cyclic
orthoform
hydrolysi
monoacet
follow
reduct
triphenylphosphin
result
product
lactol
yield
subsequ
lactol
intermedi
function
multipl
step
amid
final
step
pathway
amid
convert
psympederin
scheme
sever
divers
methodolog
synthesi
psymberin
function
congen
report
past
year
konopelski
et
al
shao
huang
et
al
addit
pietruszka
cowork
design
method
synthes
new
analogu
psymberin
includ
put
intermedi
natur
biosynthet
pathway
pietruszka
synthet
approach
psymberin
depict
scheme
evalu
biolog
potenti
therapeut
activ
class
compound
difficult
stem
low
concentr
host
organ
mycalamidea
exhibit
promis
vivo
antivir
activ
coronaviru
mice
furthermor
mycalamid
b
onnamid
show
anticanc
properti
vitro
vivo
mice
human
tumor
cell
concentr
rang
nm
three
compound
shown
inhibit
protein
synthesi
low
nanomolar
concentr
mycalamid
b
exhibit
abil
convert
transform
rat
kidney
epitheli
cell
nrk
back
normal
morpholog
possibl
select
inhibit
protein
synthesi
recent
dyshlovoy
et
al
show
mycalamid
abl
block
epiderm
growth
factorinduc
cancer
transform
murin
epiderm
cell
line
p
induc
apoptosi
subnanomolar
concentr
possibl
inhibit
nfkb
nuclear
transcript
factor
richter
et
al
show
synthet
congen
mycalamideb
ie
mycalamideb
mycalamideb
exhibit
antiprolif
effect
carcinoma
specif
cell
line
demonstr
suscept
mycalamid
mycalamid
b
onnamid
includ
murin
lymphoma
cell
human
tumor
cell
leukemia
cell
mycalamidea
also
activ
melanoma
lewi
lung
carcinoma
ovarian
sarcoma
carcinoma
human
burkitt
lymphoma
tumor
xenograft
addit
antitumor
properti
mycalamidea
demonstr
power
immunosuppress
action
potenc
inhibit
cell
approxim
time
cyclosporin
molar
basi
place
mycalamid
amongst
power
immunosuppress
compound
discov
date
mycalamid
also
shown
induc
apoptosi
prefer
myeloid
cell
ra
bcrabl
alter
mycalamid
appear
uniqu
mechan
action
great
interest
studi
immunobiolog
cell
potenti
develop
agent
modul
tcell
function
strong
immunosuppress
abil
compound
uniqu
mechan
cytotox
make
promis
potenti
biochem
tool
eg
rapamycin
alreadi
led
sever
advanc
cell
biolog
potenti
therapeut
agent
prevent
graftvshost
hostvsgraft
diseas
posttranspl
surgeri
patient
addit
agent
potenti
allevi
patient
autoimmun
disord
also
potenti
util
mycalamid
appear
substrat
major
drug
efflux
pump
pglycoprotein
therefor
pgp
expect
limit
factor
cytotox
psymberin
also
known
irciniastatin
natur
occur
cytotox
agent
independ
isol
pettit
et
al
marin
spong
psammocina
speci
crew
et
al
ircinia
ramos
speci
recent
document
psymberin
rather
produc
symbiot
bacteria
associ
marin
spong
marin
spong
psymberin
structur
featur
close
resembl
pederin
famili
member
includ
mycalamid
gener
psymberin
lack
commonli
present
acetalcontain
peder
side
chain
identifi
dihydroisocoumarin
unit
wide
found
member
pederin
famili
activ
pysmberin
variou
human
cancer
cell
line
list
tabl
cell
line
test
psymberin
display
differenti
cytotox
profil
potent
colon
cancer
melanoma
breast
cancer
cell
line
sever
research
group
attempt
synthes
fascin
marin
drug
owe
complex
structur
limit
natur
abund
biolog
properti
huang
et
al
report
sever
analogu
psymberin
construct
modifi
tetradhydropyran
ring
core
psymberin
analogu
biolog
test
use
major
human
cancer
cell
line
identifi
valu
tabl
compound
found
potent
analogu
potenc
fold
compar
psymberin
epim
modif
reveal
high
potenc
human
lung
cancer
cell
line
fig
de
braband
et
al
synthes
psymberin
analogu
whose
biolog
activ
major
human
cancer
cell
line
list
tabl
psymberin
two
epim
exhibit
meaning
valu
whose
valu
rel
lower
compar
two
hybrid
synthes
dimethoxi
unit
instead
dihydroisocoumarin
unit
structur
variat
psymberin
epim
compar
two
hybrid
indic
retent
dihydroisocoumarin
unit
essenti
biolog
activ
psymberin
furthermor
reveal
structur
alter
psymberin
could
result
decreas
cellular
uptak
compound
hela
cell
compar
psymberin
incub
hela
cell
nm
psymberin
epim
intracellular
concentr
psymberinepim
less
pysmberin
intracellular
concentr
psympederin
limit
detect
studi
employ
forward
genet
screen
c
elegan
identifi
ribosom
primari
target
psymberin
also
demonstr
contrast
pederin
psymberin
exhibit
blister
activ
due
absenc
acet
group
recent
pietruszka
group
synthes
pysmberin
put
biosynthet
precursor
psymberin
step
whose
biolog
activ
yet
determin
psymberin
exhibit
potent
antiprolif
activ
wide
select
human
tumor
cell
line
includ
rang
nm
data
pertin
differenti
sensit
variou
cell
line
psymberin
summar
tabl
crew
cowork
also
report
psymberin
exhibit
phenomen
activ
human
colon
cancer
cell
line
rang
interest
note
accord
author
ring
essenti
activ
contrast
nacylamin
function
absolut
crucial
cytotox
mycalamid
congen
initi
isol
variou
natur
sourc
garner
signific
attent
scientif
commun
recent
year
owe
limit
suppli
natur
sourc
sever
research
group
focus
biosynthesi
biolog
evalu
variou
scheme
present
chapter
highlight
select
synthet
approach
employ
prepar
structur
uniqu
motif
analog
addit
recent
advanc
synthet
approach
compound
improv
total
synthesi
compound
deriv
evalu
biolog
activ
proven
effect
extrem
low
concentr
potent
cytotox
observ
variou
cancer
cell
line
treat
mycalamid
psymberin
analog
lower
nanomolar
rang
similarli
mycalamid
also
demonstr
antivir
properti
tcellmodul
potenti
henc
advanc
class
natur
product
exemplifi
power
interdisciplinari
approach
drug
discoveri
design
newli
function
analog
potent
anticanc
antivir
immunosuppress
activ
realiz
much
remain
reveal
biolog
properti
psymberin
pederin
mycalamid
analog
reason
conclud
novel
synthet
approach
discuss
recent
review
evolv
yield
potent
highlytarget
compound
near
futur
